ATE317868T1 - Sterisch gehinderte derivate von wasserlöslichen polymeren - Google Patents

Sterisch gehinderte derivate von wasserlöslichen polymeren

Info

Publication number
ATE317868T1
ATE317868T1 AT00988240T AT00988240T ATE317868T1 AT E317868 T1 ATE317868 T1 AT E317868T1 AT 00988240 T AT00988240 T AT 00988240T AT 00988240 T AT00988240 T AT 00988240T AT E317868 T1 ATE317868 T1 AT E317868T1
Authority
AT
Austria
Prior art keywords
sterically hindered
water soluble
soluble polymers
alkyl
aryl group
Prior art date
Application number
AT00988240T
Other languages
English (en)
Inventor
Michael David Bentley
Xuan Zhao
Lihong Guo
Xiaoming Shen
Original Assignee
Nektar Therapeutics Al Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics Al Corp filed Critical Nektar Therapeutics Al Corp
Application granted granted Critical
Publication of ATE317868T1 publication Critical patent/ATE317868T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/321—Polymers modified by chemical after-treatment with inorganic compounds
    • C08G65/324—Polymers modified by chemical after-treatment with inorganic compounds containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
    • C08G65/3322—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof acyclic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT00988240T 1999-12-22 2000-12-20 Sterisch gehinderte derivate von wasserlöslichen polymeren ATE317868T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17178499P 1999-12-22 1999-12-22

Publications (1)

Publication Number Publication Date
ATE317868T1 true ATE317868T1 (de) 2006-03-15

Family

ID=22625126

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00988240T ATE317868T1 (de) 1999-12-22 2000-12-20 Sterisch gehinderte derivate von wasserlöslichen polymeren

Country Status (13)

Country Link
US (8) US6495659B2 (de)
EP (1) EP1259562B1 (de)
JP (1) JP4861586B2 (de)
KR (1) KR100653153B1 (de)
AT (1) ATE317868T1 (de)
AU (1) AU781839B2 (de)
CA (1) CA2394980C (de)
CY (1) CY1107463T1 (de)
DE (1) DE60026073T2 (de)
DK (1) DK1259562T3 (de)
ES (1) ES2256082T3 (de)
MX (1) MXPA02006216A (de)
WO (1) WO2001046291A1 (de)

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7642323B2 (en) 1997-11-06 2010-01-05 Nektar Therapeutics Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6448369B1 (en) * 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
AU766190B2 (en) 1998-10-16 2003-10-09 Biogen Idec Ma Inc. Interferon-beta fusion proteins and uses
DK1656952T3 (da) 1998-10-16 2014-01-20 Biogen Idec Inc Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
CA2394980C (en) * 1999-12-22 2008-05-13 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
US6602498B2 (en) * 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
CA2414076A1 (en) 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
US7053150B2 (en) 2000-12-18 2006-05-30 Nektar Therapeutics Al, Corporation Segmented polymers and their conjugates
US7056500B2 (en) 2001-10-18 2006-06-06 Nektar Therapeutics Al, Corporation Polymer conjugates of opioid antagonists
PT3025726T (pt) * 2002-01-18 2020-01-09 Biogen Ma Inc Compostos do polímero polialquileno e utilizações dos mesmos
CN100337689C (zh) * 2002-07-24 2007-09-19 弗·哈夫曼-拉罗切有限公司 聚亚烷基二醇酸加合物
US7569214B2 (en) 2002-09-09 2009-08-04 Nektar Therapeutics Al, Corporation Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid
JP4764630B2 (ja) 2002-09-09 2011-09-07 ネクター セラピューティックス 水溶性ポリマーアルカナール
US20050130892A1 (en) * 2003-03-07 2005-06-16 Xencor, Inc. BAFF variants and methods thereof
US20060014248A1 (en) * 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US20050221443A1 (en) * 2003-01-06 2005-10-06 Xencor, Inc. Tumor necrosis factor super family agonists
US7553930B2 (en) * 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
EP2330213A1 (de) 2003-03-05 2011-06-08 Halozyme, Inc. Lösliches Hyaluronidaseglykoprotein (sHASEGP), Verfahren zu dessen Herstellung, Verwendungen und pharmazeutische Zusammensetzunge, die dieses umfassen
US7642340B2 (en) 2003-03-31 2010-01-05 Xencor, Inc. PEGylated TNF-α variant proteins
US7587286B2 (en) * 2003-03-31 2009-09-08 Xencor, Inc. Methods for rational pegylation of proteins
US7610156B2 (en) * 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
US7892993B2 (en) 2003-06-19 2011-02-22 Eastman Chemical Company Water-dispersible and multicomponent fibers from sulfopolyesters
US8513147B2 (en) 2003-06-19 2013-08-20 Eastman Chemical Company Nonwovens produced from multicomponent fibers
US20040260034A1 (en) 2003-06-19 2004-12-23 Haile William Alston Water-dispersible fibers and fibrous articles
US7482376B2 (en) * 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
WO2005006964A2 (en) 2003-07-18 2005-01-27 Broncus Technologies, Inc. Devices for maintaining patency of surgically created channels in tissue
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
CN1852740B (zh) 2003-09-17 2011-05-11 耐科塔医药公司 多支链聚合物的药物前体
EP1675871A2 (de) 2003-10-10 2006-07-05 Xencor Inc. Tnf-alpha-varianten auf proteinbasis zur behandlung von erkrankungen in verbindung mit tnf-alpha
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
CN1925875A (zh) * 2003-12-16 2007-03-07 尼克塔治疗亚拉巴马公司 化学改性的小分子
WO2005067644A2 (en) * 2004-01-07 2005-07-28 Ambit Biosciences Corporation Conjugated small molecules
EP1756173B1 (de) * 2004-01-21 2019-04-03 Nektar Therapeutics Verfahren zur herstellung von propionsäureterminierten polymeren
BRPI0507169A (pt) * 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
WO2005091944A2 (en) * 2004-03-17 2005-10-06 Eli Lilly And Company Glycol linked fgf-21 compounds
JP2008505853A (ja) 2004-04-13 2008-02-28 クインテセンス バイオサイエンシーズ インコーポレーティッド 細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体
EP1771205B1 (de) 2004-06-18 2016-10-26 Ambrx, Inc. Neuartige antigen-bindende polypeptide und ihre verwendungen
JP2008506703A (ja) 2004-07-14 2008-03-06 ユニバーシティ オブ ユタ リサーチ ファウンデーション ネトリン関連化合物および用途
JP2008507280A (ja) * 2004-07-21 2008-03-13 アンブレツクス・インコーポレイテツド 非天然コードアミノ酸を用いた生合成ポリペプチド
US7612153B2 (en) * 2004-10-25 2009-11-03 Intezyne Technologies, Inc. Heterobifunctional poly(ethylene glycol) and uses thereof
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
JP2008525032A (ja) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 組換えヒト成長ホルモンを発現及び精製するための方法
BRPI0519170A8 (pt) 2004-12-22 2018-05-08 Ambrx Inc formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado
CA2594557C (en) 2004-12-22 2016-04-26 Ambrx, Inc. Modified human growth hormone
JP4990792B2 (ja) 2004-12-22 2012-08-01 アンブレツクス・インコーポレイテツド アミノアシル−ｔＲＮＡシンテターゼの組成物およびこの使用
US7714114B2 (en) * 2005-02-16 2010-05-11 Nektar Therapeutics Conjugates of an EPO moiety and a polymer
US20060233740A1 (en) * 2005-03-23 2006-10-19 Bossard Mary J Conjugates of an hGH moiety and a polymer
SI1881850T1 (sl) 2005-05-13 2011-01-31 Lilly Co Eli Glp-1 pegilirane spojine
EP1885404A2 (de) * 2005-06-01 2008-02-13 Alza Corporation Biokonjugationsreaktionen für acylierende polyethylenglykol reagentien
KR20080026135A (ko) 2005-06-03 2008-03-24 암브룩스, 인코포레이티드 개선된 인간 인터페론 분자 및 이의 용도
WO2007021297A1 (en) 2005-08-18 2007-02-22 Ambrx, Inc. COMPOSITIONS OF tRNA AND USES THEREOF
EP1951890A4 (de) 2005-11-16 2009-06-24 Ambrx Inc Verfahren und zusammensetzungen mit nichtnatürlichen aminosäuren
KR101423898B1 (ko) * 2005-12-14 2014-07-28 암브룩스, 인코포레이티드 비-천연 아미노산 및 폴리펩티드를 함유하는 조성물, 비-천연 아미노산 및 폴리펩티드를 포함하는 방법, 및 비-천연 아미노산 및 폴리펩티드의 용도
US7635745B2 (en) 2006-01-31 2009-12-22 Eastman Chemical Company Sulfopolyester recovery
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
AU2007233116B2 (en) * 2006-03-30 2013-05-09 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
US8580746B2 (en) * 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
AU2007233123A1 (en) * 2006-03-30 2007-10-11 Palatin Technologies, Inc. Linear natriuretic peptide constructs
EP2004231A4 (de) 2006-04-07 2013-07-10 Nektar Therapeutics Konjugate eines anti-tnf-alpha-antikörpers
EP2007804B1 (de) 2006-04-20 2014-06-18 Amgen, Inc Glp-1-verbindungen
US7560588B2 (en) 2006-04-27 2009-07-14 Intezyne Technologies, Inc. Poly(ethylene glycol) containing chemically disparate endgroups
US8840882B2 (en) 2006-06-23 2014-09-23 Quintessence Biosciences, Inc. Modified ribonucleases
WO2008010991A2 (en) 2006-07-17 2008-01-24 Quintessence Biosciences, Inc. Methods and compositions for the treatment of cancer
AU2007292892B9 (en) 2006-09-08 2013-02-28 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
KR20090060294A (ko) 2006-09-08 2009-06-11 암브룩스, 인코포레이티드 변형된 인간 혈장 폴리펩티드 또는 Ｆｃ 스캐폴드 및 그의 용도
CN101511856B (zh) 2006-09-08 2016-01-20 Ambrx公司 脊椎动物细胞中抑制因子trna的转录
MX2009005780A (es) 2006-11-30 2009-06-10 Nektar Therapeutics Al Corp Metodo para preparar un conjugado de polimeros.
WO2008088983A1 (en) 2007-01-18 2008-07-24 Eli Lilly And Company PEGYLATED Aβ FAB
MX2009008549A (es) * 2007-02-09 2009-08-18 Enzon Pharmaceuticals Inc Tratamiento de canceres resistentes o refractarios con conjugados polimericos de brazos multiples de 7-etil-10-hidroxicamptotecina.
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
CN101675071B (zh) 2007-05-02 2014-06-18 Ambrx公司 经修饰干扰素β多肽和其用途
KR100979462B1 (ko) 2007-08-03 2010-09-02 한국화학연구원 안트라사이클라인계 항암약물 봉입용 리포솜 및 이의제조방법
CA2702043A1 (en) * 2007-10-08 2009-04-16 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapies
CA2703830A1 (en) 2007-11-20 2009-05-28 Ambrx, Inc. Modified insulin polypeptides and their uses
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
WO2009128917A2 (en) 2008-04-14 2009-10-22 Halozyme, Inc. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
EP2318029B1 (de) 2008-07-23 2017-11-01 Ambrx, Inc. Modifizierte bovine g-csf-polypeptide und ihre verwendung
KR101671537B1 (ko) * 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
KR101660059B1 (ko) * 2008-08-22 2016-09-26 박스알타 인코퍼레이티드 중합체 벤질 카르보네이트-유도체
TW201010732A (en) * 2008-08-29 2010-03-16 Enzon Pharmaceuticals Inc Method of treating RAS associated cancer
EP2331139B1 (de) * 2008-09-11 2019-04-17 Nektar Therapeutics Polymer-alpha-hydroxy-aldehyd und keton-reagenzien und konjugationsverfahren
EP2350118B1 (de) 2008-09-19 2016-03-30 Nektar Therapeutics Kohlenhydratbasisierte polymere zur wirkstoffabgabe und konjugate davon
EP2340047A1 (de) * 2008-09-19 2011-07-06 Nektar Therapeutics Polymerkonjugate von kiss1-peptiden
US20110171164A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
US20110206633A1 (en) * 2008-09-19 2011-08-25 Nektar Therapectics Polymer conjugates of cd-np peptides
US20110171162A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of thymosin alpha 1 peptides
US20110171166A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of osteocalcin peptides
EP2340046A2 (de) * 2008-09-19 2011-07-06 Nektar Therapeutics Polymerkonjugate von ziconotid-peptiden
WO2010033204A2 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of c-peptides
WO2010033223A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of opioid growth factor peptides
EP2340045B1 (de) 2008-09-19 2017-04-12 Nektar Therapeutics Polymerkonjugate aus protegrin-peptiden
AU2009292651A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of AOD-like peptides
US20110165113A1 (en) * 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of v681-like peptides
MX2011003063A (es) 2008-09-23 2011-04-21 Nektar Therapeutics Composiciones y metodos para lograr concentraciones terapeuticas de farmaco sostenidas en un individuo.
US8278418B2 (en) 2008-09-26 2012-10-02 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
PE20110480A1 (es) 2008-09-26 2011-07-01 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales
BRPI0920743A2 (pt) 2008-10-01 2016-09-20 Quintessence Biosciences Inc ribonucleases terapeuticas
US20100098654A1 (en) * 2008-10-21 2010-04-22 Fabio Pastorino Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
CN102307993B (zh) 2008-12-09 2014-06-25 哈洛齐梅公司 延长的可溶性ph20多肽及其用途
US8512519B2 (en) 2009-04-24 2013-08-20 Eastman Chemical Company Sulfopolyesters for paper strength and process
PT2477603E (pt) 2009-09-17 2016-06-16 Baxalta Inc Co-formulação estável de hialuronidase e imunoglobulina e métodos para a sua utilização
DE102009045969B4 (de) 2009-10-23 2019-01-31 Technische Universität Bergakademie Freiberg Verfahren und Mittel zur Spaltung von Estern, Amiden und Thioestern der Ameisensäure
JP5885668B2 (ja) 2009-12-02 2016-03-15 アダマス ファーマシューティカルズ， インコーポレイテッド アマンタジン組成物および使用方法
JP2013515081A (ja) 2009-12-21 2013-05-02 アンブルックス，インコーポレイテッド 修飾されているブタのソマトトロピンポリペプチドおよびそれらの使用
EA201290541A1 (ru) 2009-12-21 2013-05-30 Амбркс, Инк. Модифицированные бычьи соматотропиновые полипептиды и их применение
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
JO2976B1 (en) 2009-12-22 2016-03-15 ايلي ليلي اند كومباني Axentomodulin polypeptide
JP2013533217A (ja) 2010-05-17 2013-08-22 セビックス・インコーポレイテッド Ｐｅｇ化ｃ−ペプチド
US20130217871A1 (en) 2010-07-09 2013-08-22 Helmut Knoller Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation
WO2012004007A1 (en) 2010-07-09 2012-01-12 Fresenius Kabi Deutschland Gmbh Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation
DK2595624T3 (en) 2010-07-20 2018-03-26 Halozyme Inc Methods of treating or preventing adverse side effects associated with administration of an anti-hyaluronan agent
PE20140160A1 (es) 2010-08-17 2014-02-08 Ambrx Inc Polipeptidos de relaxina modificados y sus usos
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
SI2621496T2 (sl) 2010-09-30 2019-04-30 Astrazeneca Ab Kristalinični konjugat naloksol-PEG
US20120183861A1 (en) 2010-10-21 2012-07-19 Eastman Chemical Company Sulfopolyester binders
WO2012054822A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Pharmacologically active polymer-glp-1 conjugates
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
MX371466B (es) 2010-12-01 2020-01-28 Huntsman Petrochemical Llc Aminas inhibidas estericamente y metodos asociados.
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
EP2907504B1 (de) 2011-02-08 2017-06-28 Halozyme, Inc. Zusammensetzung und Lipidformulierung eines Hyaluronan-abbauenden Enzyms und seiner Verwendung zur Behandlung von benigner Prostatahyperplasie
US20130022592A1 (en) 2011-06-17 2013-01-24 Daniel Edward Vaughn Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
EP2720712B1 (de) 2011-06-17 2016-03-02 Halozyme, Inc. Stabile formulierungen eines hyaluronan-abbauenden enzyms
US20130071394A1 (en) 2011-09-16 2013-03-21 John K. Troyer Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
CA2853358A1 (en) 2011-10-24 2013-05-02 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
US8962553B2 (en) 2011-11-17 2015-02-24 Cebix Ab Method of treating a diabetic subject having a microvascular impairment disorder by a pegylated C-peptide
SG11201403714TA (en) 2011-12-30 2014-07-30 Halozyme Inc Ph20 polypeptide variants, formulations and uses thereof
US8882963B2 (en) 2012-01-31 2014-11-11 Eastman Chemical Company Processes to produce short cut microfibers
EP2833905B1 (de) 2012-04-04 2018-05-02 Halozyme, Inc. Kombinationbehnadlung von hyaluronidase und einem tumor-gerichteten taxane
US9738724B2 (en) 2012-06-08 2017-08-22 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP3135690A1 (de) 2012-06-26 2017-03-01 Sutro Biopharma, Inc. Modifizierte fc-proteine mit stellenspezifischen nichtnatürlichen aminosäureresten, konjugate daraus, verfahren zu deren herstellung und verfahren zu deren verwendung
SI2890402T1 (sl) 2012-08-31 2019-07-31 Sutro Biopharma, Inc. Modificirane aminokisline vsebujoče acido skupino
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
US9617685B2 (en) 2013-04-19 2017-04-11 Eastman Chemical Company Process for making paper and nonwoven articles comprising synthetic microfiber binders
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
WO2015081891A1 (en) 2013-12-06 2015-06-11 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
US9598802B2 (en) 2013-12-17 2017-03-21 Eastman Chemical Company Ultrafiltration process for producing a sulfopolyester concentrate
US9605126B2 (en) 2013-12-17 2017-03-28 Eastman Chemical Company Ultrafiltration process for the recovery of concentrated sulfopolyester dispersion
CN106795506B (zh) 2014-05-14 2020-11-27 达特茅斯学院理事会 去免疫化溶葡萄球菌酶和使用方法
EP3186281B1 (de) 2014-08-28 2019-04-10 Halozyme, Inc. Kombinationstherapie mit einer hyaluronanabbauendem enzym und einem immun-checkpoint-hemmer
AU2015332533B2 (en) 2014-10-14 2018-08-30 Halozyme, Inc. Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
MX2017004947A (es) 2014-10-24 2017-06-29 Bristol Myers Squibb Co Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
JP6949102B2 (ja) 2016-08-09 2021-10-13 イーライ リリー アンド カンパニー 併用療法
SG10201912034UA (en) 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US12344645B2 (en) 2017-03-29 2025-07-01 Polaris Group Protein conjugates
PE20200697A1 (es) 2017-06-22 2020-06-16 Catalyst Biosciences Inc Polipeptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y metodos de uso
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
US11897917B2 (en) 2017-09-27 2024-02-13 The University Of York Bioconjugation of polypeptides
KR102777151B1 (ko) 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
KR20210057124A (ko) 2018-09-11 2021-05-20 암브룩스, 인코포레이티드 인터류킨-2 폴리펩타이드 접합체 및 그의 용도
JP2022512746A (ja) 2018-10-19 2022-02-07 アンブルックス，インコーポレイテッド インターロイキン－１０ポリペプチド複合体、その二量体、およびそれらの使用
JP7604376B2 (ja) 2018-12-28 2024-12-23 バーテックス ファーマシューティカルズ インコーポレイテッド 改変ウロキナーゼ型プラスミノゲンアクティベータポリペプチドおよび使用方法
CN119455003A (zh) 2019-02-12 2025-02-18 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
US11377173B1 (en) 2019-07-30 2022-07-05 Christopher T. Stanton Automated cover support and method
CN115362168A (zh) 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
EP4117732A1 (de) 2020-03-11 2023-01-18 Ambrx, Inc. Interleukin-2-polypeptidkonjugate und verfahren zur verwendung davon
CA3128035A1 (en) 2020-08-13 2022-02-13 Bioasis Technologies, Inc. Combination therapies for delivery across the blood brain barrier
WO2022040596A1 (en) 2020-08-20 2022-02-24 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
WO2022212899A1 (en) 2021-04-03 2022-10-06 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof
WO2025227129A2 (en) 2024-04-25 2025-10-30 Starrock Pharma Llc Delivery vehicles comprising proglucagon derived polypeptides and anabolic polypeptides and uses thereof
US20250341516A1 (en) 2024-05-01 2025-11-06 BioLegend, Inc. Compositions for use with multiple fluorophores and methods of using
WO2026043823A2 (en) 2024-08-19 2026-02-26 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6397606A (ja) 1986-10-14 1988-04-28 Toshinobu Higashimura 側鎖に水酸基を有するポリアルケニルエ−テル
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5349001A (en) 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
ES2211033T3 (es) * 1998-01-07 2004-07-01 Debio Recherche Pharmaceutique S.A. Acrilatos de polietilenglicol heterobifuncionales degradables y geles y conjugados derivados de dichos acrilatos.
CA2323048C (en) * 1998-03-12 2006-10-10 Shearwater Polymers, Inc. Poly(ethylene glycol) derivatives with proximal reactive groups
CA2394980C (en) 1999-12-22 2008-05-13 Shearwater Corporation Sterically hindered derivatives of water soluble polymers

Also Published As

Publication number Publication date
US20020002250A1 (en) 2002-01-03
US20110207896A1 (en) 2011-08-25
US7405266B2 (en) 2008-07-29
US7960502B2 (en) 2011-06-14
US20100121019A1 (en) 2010-05-13
US20080262166A1 (en) 2008-10-23
US20060069237A1 (en) 2006-03-30
ES2256082T3 (es) 2006-07-16
MXPA02006216A (es) 2004-02-26
KR100653153B1 (ko) 2006-12-01
JP2003518178A (ja) 2003-06-03
US20070179274A1 (en) 2007-08-02
US8183338B2 (en) 2012-05-22
US6737505B2 (en) 2004-05-18
AU2446901A (en) 2001-07-03
DK1259562T3 (da) 2006-04-18
DE60026073D1 (de) 2006-04-20
EP1259562A1 (de) 2002-11-27
CY1107463T1 (el) 2013-09-04
US20050008612A1 (en) 2005-01-13
US7674879B2 (en) 2010-03-09
WO2001046291A1 (en) 2001-06-28
US6495659B2 (en) 2002-12-17
EP1259562B1 (de) 2006-02-15
US7205380B2 (en) 2007-04-17
DE60026073T2 (de) 2006-09-28
AU781839B2 (en) 2005-06-16
US20030105275A1 (en) 2003-06-05
KR20020074459A (ko) 2002-09-30
JP4861586B2 (ja) 2012-01-25
CA2394980C (en) 2008-05-13
CA2394980A1 (en) 2001-06-28
US6992168B2 (en) 2006-01-31

Similar Documents

Publication Publication Date Title
DE60026073D1 (de) Sterisch gehinderte derivate von wasserlöslichen polymeren
TW200631604A (en) Ophthalmic compositions comprising polyether substituted polymers
AU5511101A (en) Aldehyde-containing polymers as wet strength additives
FI955320A0 (fi) Bioaktiivisia ja/tai kohdennettuja dendriimikonjugaatteja
DE60033969D1 (de) Hydrolytisch abbaubare carbamatderivate von polyethylenglykol
NZ592139A (en) Biodegradable polymer - bioactive moiety conjugates
ID30325A (id) Komposisi polimer emisi rendah
AU3129895A (en) Non-antigenic amine derived polymers and polymer conjugates
WO2007004067A3 (en) Methods and compositions for the delivery of biologically active agents
DE50002486D1 (de) Wasserabsorbierende polymere mit hohlraumverbindungen, verfahren zu deren herstellung und deren verwendung
IL142068A0 (en) Compositions containing a derivative of hyaluronic acid and methods for the preparation thereof
WO2006053299A3 (en) Site-directed modification of fviii
ATE425767T1 (de) Konjugate von cyanovirin-varianten und einem polyalkylenoxid
AU7805201A (en) Therapeutic polyanhydride compounds for drug delivery
MXPA04004026A (es) Conjugados polimericos de inhibidores de la proteina quinasa c.
ATE270788T1 (de) Verfahren zur dotierung von polymeren
DE60214853D1 (de) Biologisch abbaubare kaugummigrundmasse
WO2002043772A3 (en) Water-soluble polymer conjugates of triazine derivatives
ATE268609T1 (de) Polyethylenglycolderivate mit benachbarten reaktiven gruppen
DE60044030D1 (de) Markerkomplexe aus konjugierten polymeren
TR200200358T2 (tr) Büyüme sonrası herbisitlerden toprağa uygulananlara kadar herbisit maddeler.
WO2005107815A3 (en) Polymer derivatives comprising an imide branching point
ATE317703T1 (de) Polymer-wirkstoff-konjugate zur behandlung von krebs
DK1274749T3 (da) Antimikrobielle polymeriske sammensætninger
ATE328918T1 (de) Verbesserte silanefunktionelle olefin- interpolymere derivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1259562

Country of ref document: EP